The following is a summary of “Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With Human Immunodeficiency Virus,” published in the March 2024 issue of Infectious Diseases by Nguyen et al.
People with HIV (PWH) often face metabolic issues such as weight increase. Hence, effective interventions are also necessary to tackle this issue.
Researchers conducted a retrospective investigation on patients with HIV who received Glucagon-like peptide-1 receptor agonists (GLP-1RAs) treatment to examine its impact on people with HIV and weight reduction.
They analyzed PWH undergoing GLP-1RAs therapy at San Diego Owen Clinic between 2021 and 2023. Baseline clinical data and changes in weight, body mass index (BMI), and hemoglobin A1C (A1C) were collected and compared with most recent clinical visit data (3 months follow-up time) before starting GLP-1RAs. If >5% of total body weight loss occurred, logistic regression was performed to identify variables associated with it.
The result showed 225 patients received 13 months of GLP-1RA therapy on average, with 85 (37.8%) achieving the maximum GLP-1RA dose. Therapy showed mean weight loss of 5.4 kg, a decrease in BMI by 1.8g/m2, and a decrease in A1C by 0.6%. In multivariable analysis, higher baseline BMI [OR 1.10 (1.03-1.16)], GLP-1RA therapy duration >6 months [OR 3.12 (1.49-6.49)], and tirzepatide use [OR 5.46 (1.44-20.76)] significantly associated with >5% weight loss.
Investigators concluded that GLP-1RAs could lead to a significant loss in Weight, BMI, and A1C among PWH.
Source: academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciae151/7631407